OXTR and Ventricular arrhythmia: Importantly, intravenous administration of the oxytocin receptor antagonist, retosiban, completely prevented the MI-induced increase in cardiac SNA, which likely contributed to the reduced incidence of ventricular arrhythmias and improve survival.